Altimmune adds Lonza as a Manufacturing Partner for supply of AdCOVID,

▴ Altimmune adds Lonza as a Manufacturing Partner for supply of AdCOVID,
AdCovid is its single-dose Intranasal vaccine candidate for COVID-19

Gaithersburg, USA and Basel, Switzerland, 10 November 2020 – Altimmune, Inc., a clinical-stage biopharmaceutical company, today announced that entered into an agreement with Lonza for the manufacturing of AdCOVID, Altimmune’s next-generation, a single-dose intranasal vaccine candidate for COVID-19. Lonza is a leading global biopharmaceutical manufacturing company with facilities in Europe, North America, and South Asia.

AdCOVID is a single-dose COVID-19 vaccine candidate that has the potential to be conveniently administered via an intranasal spray. In addition to activating systemic immunity (neutralizing antibodies and T cell responses), AdCOVID stimulates a type of localized immunity called mucosal immunity, which can act to prevent both SARS-CoV-2 virus infection and transmission.

In preclinical studies, AdCOVID produced a 29-fold increase in mucosal IgA, well above the level associated with protection observed in several clinical studies from influenza, another respiratory virus.

Based on clinical experience with the Altimmune’s vaccine platform technology, AdCOVID is expected to provide durable immunity of up to a year or more following a single dose and to have an excellent tolerability and stability profile. Vaccine stability is critical for efficient vaccine deployment and AdCOVID is expected to be shipped without a cold chain and permit common refrigerated storage conditions at community-based vaccination centers without the need for specialized freezer storage.

“We are excited about the potential of our AdCOVID vaccine candidate and are actively focused on expanding our network of strategic manufacturing partners to ensure Altimmune’s commercial readiness to supply vaccine in 2021 should our clinical data support this advancement. Lonza is a tremendous partner in this mission, with deep expertise and experience in vector manufacturing and global world-class facilities capable of manufacturing AdCOVID at commercial scale.” said Dr. Vyjoo Krishnan, Vice President of Product Development, Altimmune.

Tags : #Altimmune #Lonza #AdCovid #IntranasalCovidVaccine #LatestPharmaNewsNov10 #MucosalIgA

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

10 PCOS Warning Signs That Need Your AttentionDecember 27, 2024
Experts Dub 2024 as the Year of Technologies and Innovations in Healthcare; Stress on further Integration of Technologies December 27, 2024
Aakash Healthcare Partners with Japan for Groundbreaking Surgical Intervention: A Global Collaboration to Revolutionize Cardiovascular CareDecember 26, 2024
Traditional Medicine Goes Global: How Ayush 2024 Reimagined WellnessDecember 26, 2024
Aster Guardians Global Nursing Award 2025 worth INR 2 Crore now open for nominations worldwide December 26, 2024
Holiday Season Round the Corner? 6 Daily Habits That Could Be The Reason Behind Your Fatty LiverDecember 26, 2024
Healing the Nation: Doctors as Architects of a Healthier FutureDecember 26, 2024
Brewing Health Benefits: Can Coffee and Tea Help Fight Head and Neck Cancers?December 26, 2024
Seven-Year-Old Fights Back Against Rare Autoimmune DiseaseDecember 26, 2024
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive YearDecember 26, 2024
American Oncology Institute (AOI) in Nagpur Restores Mobility with KyphoplastyDecember 26, 2024
Sanjeevani Healthcare & Wellness Expo 2024: A Dynamic Platform for Global Healthcare CollaborationDecember 23, 2024
Ranitidine: Saviour or Suspect? The Truth Behind the Stomach Acid RemedyDecember 23, 2024
From One-Size-Fits-All to Precision Medicine: The New Hope for Rare Bone Cancer PatientsDecember 23, 2024
World Meditation Day: India’s Gift of Peace to a Chaotic WorldDecember 23, 2024
Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and TreatmentDecember 23, 2024
Black Angels remind us of centuries of injustices plaguing the TB responseDecember 20, 2024
Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024